Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Go back to Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib| (NASDAQ: KURA) | Delayed: 10.36 +0.43 (4.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.93 | 52 Week High | $8.90 | |||
| Open | $9.96 | 52 Week Low | $2.50 | |||
| Day High | $10.54 | P/E | N/A | |||
| Day Low | $9.95 | EPS | $0.00 | |||
| Volume | 1,383,616 | |||||
